Regenxbio Inc (OQ:RGNX)

May 10, 2024 07:05 am ET
REGENXBIO to Participate in Upcoming Investor Conferences
ROCKVILLE, Md., May 10, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor conferences:
May 08, 2024 04:05 pm ET
REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational Highlights
Company remains on track for its first BLA filing in 2024 and is accelerating progress toward pivotal trial initiation for Duchenne (H2 2024) and diabetic retinopathy (H1 2025)Dose level 2 selected as pivotal dose for RGX-202 treatment of DuchenneNew positive interim efficacy and safety data announced for second boy at DL2 AFFINITY DUCHENNE® trial expansion phase is underway with third and fourth boys dosed at DL2End-of-Phase II meeting with FDA planned for early Q3 and pivotal trial initiation anticipated in late Q3 to early Q4 2024Positive interim results from ALTITUDE® trial for diabetic
May 01, 2024 07:05 am ET
REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights
ROCKVILLE, Md., May 1, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Wednesday, May 8, 2024, at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2024, and recent operational highlights.
Apr 24, 2024 07:05 am ET
REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
ROCKVILLE, Md., April 24, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on Monday, April 29, 2024.
Mar 28, 2024 07:05 am ET
REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD
A single ABBV-RGX-314 gene therapy treatment has the potential to become a new standard-of-care option among anti-VEGF treatments by sustaining vision health long term and overcoming the clinical challenges of managing wet AMD due to the treatment burden of chronic anti-VEGF injectionsPatients who received therapeutic doses resulted in stable or improved vision and retinal anatomy up to 2 yearsAdditional long-term follow-up data has demonstrated durable treatment effect, with stable or improved vision, up to 4 yearsEnrollment is on track in pivotal trials of ABBV-RGX-314 in wet AMD that are
Mar 27, 2024 04:05 pm ET
REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days
ROCKVILLE, Md., March 27, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days on Wednesday, April 3, 2024.
Feb 21, 2024 06:05 am ET
REGENXBIO to Host Conference Call on February 27 to Discuss Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
ROCKVILLE, Md., Feb. 21, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Tuesday, February 27, 2024, at 4:30 p.m. ET to discuss its financial results for the fourth quarter and full year ended December 31, 2023, and recent operational highlights.
Feb 07, 2024 10:40 am ET
REGENXBIO Announces Pivotal Trial of RGX-121 for the Treatment of MPS II Achieves Primary Endpoint
Results support BLA submission in 2024 using the accelerated approval pathwayPrimary endpoint of patients achieving reduction in CSF biomarker of MPS II disease was met with statistical significance (p value of 0.00016) Patients treated with RGX-121 have showed continued improvement in neurodevelopmental skill acquisition up to four years and discontinued intravenous enzyme therapyCompany plans to discuss these results as part of a full rare disease program update on its conference call today, Wednesday, February 7, 4:30 p.m. ETROCKVILLE, Md., Feb. 7, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nas
Feb 07, 2024 06:05 am ET
REGENXBIO Announces Completion of Enrollment in Cohort 2 and Additional Positive Interim Data in AFFINITY DUCHENNE® Trial
Completed enrollment in cohort 2 of the Phase I/II AFFINITY DUCHENNE® trial of RGX-202, a potential one-time AAV Therapeutic for the treatment of Duchenne that includes an optimized transgene for a novel microdystrophinNew three-month assessment in third patient at dose level 1 demonstrates largest increase in microdystrophin expression Patient aged 6.6 years old had expression level at 83.4% of controlOn track to initiate pivotal trial in second half of 2024 Company plans to discuss these new results as part of a full rare disease program update on its conference call today, Wednesday, Febr
Jan 31, 2024 06:05 am ET
REGENXBIO Announces Presentations at the 20th Annual WORLDSymposium 2024
Pivotal topline results from the CAMPSIITE® trial of RGX-121 for the treatment of MPS II to be presentedConference call Wednesday, February 7, 4:30 p.m. ETROCKVILLE, Md., Jan. 31, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations on its program for the treatment of mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, will be shared at the 20th Annual WORLDSymposium™ 2024, taking place in San Diego, CA February 3-9, 2024.
Jan 16, 2024 01:47 pm ET
REGENXBIO Announces Positive Interim Data from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery
A single ABBV-RGX-314 gene therapy treatment has the potential to become a new standard-of-care option among anti-VEGF treatments by sustaining vision health long term and overcoming the clinical challenges of managing wet AMD due to the treatment burden of chronic anti-VEGF injections ABBV-RGX-314 continues to be well tolerated in over 100 patients from three dose levels with no drug-related serious adverse eventsABBV-RGX-314 in over 50 patients at third dose level demonstrated highest reduction in treatment burden:80% reduction in annualized injection rate50% injection-freeZero cases of in
Jan 10, 2024 06:05 am ET
REGENXBIO Announces Presentation at the Hawaiian Eye and Retina 2024 Meeting
ROCKVILLE, Md., Jan. 10, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present data from the Phase II AAVIATE® trial of suprachoroidal ABBV-RGX-314 for the treatment of wet age-related macular degeneration (AMD) at Hawaiian Eye and Retina 2024 Meeting being held January 13-19, 2024 in Maui, HI. ABBV-RGX-314 is an investigational one-time AAV Therapeutic being developed in collaboration with AbbVie for the treatment of wet AMD, diabetic retinopathy and other additional chronic retinal conditions.
Jan 08, 2024 06:05 am ET
U.S. District Court Issues Decision on REGENXBIO and University of Pennsylvania NAV® Technology Patent Infringement Lawsuit
ROCKVILLE, Md., Jan. 8, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the U.S. District Court for the District of Delaware granted Sarepta Therapeutics, Inc. (Sarepta) summary judgment on invalidity in a patent infringement suit arising from Sarepta's manufacture and use of cultured host cell technology covered by a University of Pennsylvania (Penn) patent that Sarepta uses to make clinical and commercial supplies of SRP-9001 (also known as ELEVIDYS in the U.S.), for itself and Roche, for the treatment of Duchenne muscular dystrophy. REGENXBIO intends to file an immediat
Nov 29, 2023 06:05 am ET
REGENXBIO Announces Dose Escalation in AFFINITY DUCHENNE® Trial
First patient received dose level 2 of RGX-202, a potential one-time AAV Therapeutic for the treatment of Duchenne that includes an optimized transgene for a novel microdystrophin On track for pivotal dose determination and initiation of pivotal program in 2024 ROCKVILLE, Md., Nov. 29, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that the first patient received RGX-202 at dose level 2 in the Phase I/II AFFINITY DUCHENNE® trial. RGX-202 is an investigational one-time AAV Therapeutic for Duchenne muscular dystrophy (Duchenne), using the NAV® AAV8 vector to deliver a trans
Nov 08, 2023 03:05 pm ET
REGENXBIO Announces Updated Strategic Plans and Third Quarter 2023 Financial Results
Announces pipeline prioritization and corporate restructuring to focus on clinical stage AAV Therapeutic product candidates addressing large commercial opportunities and value generation Highest priority programs are ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, RGX-202 for the treatment of Duchenne, and RGX-121 for the treatment MPS IIRestructuring plan, including a 15% reduction in workforce, expected to result in total savings of at least $100 million Anticipated cost savings from corporate restructuring, along with $365
Nov 07, 2023 06:05 am ET
REGENXBIO to Participate in Upcoming Investor Conferences
ROCKVILLE, Md., Nov. 7, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate the following upcoming investor conferences:
Nov 03, 2023 06:53 pm ET
REGENXBIO Presents Positive One Year Data from Phase II ALTITUDE® Trial of ABBV-RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery
ABBV-RGX-314 continues to be well tolerated in 50 patients from dose levels 1 and 2 (Cohorts 1-3) with no drug-related serious adverse eventsDose level 2 prevented disease progression and reduced vision-threatening events in non-proliferative diabetic retinopathy patients at 1 Year 70.8% of patients achieved Diabetic Retinopathy Severity Scale improvement vs. 25.0 % in control  0% of patients worsened ≥2 steps vs. 37.5 % in control ABBV-RGX-314 reduced vision-threatening events by 89% compared to control Conference call Monday, November 6, 8:30 a.m. ETROCKVILLE, Md., Nov. 3, 2023 /PRNewswire
Nov 01, 2023 07:05 am ET
REGENXBIO to Host Conference Call on November 8 to Discuss Third Quarter 2023 Financial Results and Recent Operational Highlights
ROCKVILLE, Md., Nov. 1, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Wednesday, November 8, 2023, at 4:30 p.m. EST to discuss its financial results for the quarter ended September 30, 2023, and recent operational highlights.
Oct 30, 2023 07:05 am ET
REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2023 Annual Meeting
ROCKVILLE, Md., Oct. 30, 2023 /PRNewswire/ --  REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the American Academy of Ophthalmology (AAO) 2023 Annual Meeting being held November 3-6, 2023 in San Francisco, CA. The presentations will highlight new data for ABBV-RGX-314, an investigational one-time AAV Therapeutic being developed in collaboration with AbbVie for the treatment of wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other additional chronic retinal conditions.
Oct 05, 2023 07:05 am ET
REGENXBIO to Participate in the Jefferies CNS/Neuro Summit
ROCKVILLE, Md., Oct. 5, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the Jefferies CNS/Neuro Summit on Thursday, October 12, 2023.
Oct 03, 2023 04:05 pm ET
REGENXBIO Presents Interim Clinical Data from Phase I/II AFFINITY DUCHENNE™ Trial of RGX-202 at 28th Annual International Congress of the World Muscle Society
RGX-202, a potential one-time AAV Therapeutic for the treatment of Duchenne that includes an optimized transgene for a novel microdystrophin, continues to be well-tolerated in three patients from dose level 1 (1x1014 GC/kg)Initial biomarker data in two patients who completed three-month assessment demonstrate robust microdystrophin expression with localization to the muscle cell membrane Patient aged 4.4 years old had expression level at 38.8% of controlTrial dose escalation expected by end of 2023Pivotal dose determination and initiation of pivotal program anticipated in 2024Plan to use RGX
Sep 26, 2023 07:05 am ET
REGENXBIO Announces Presentations at the 28th Annual Congress of the World Muscle Society
ROCKVILLE, Md., Sept. 26, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the 28th Annual Congress of the World Muscle Society, taking place in Charleston, SC from October 3-7, 2023. Presentations include interim data from the Phase I/II AFFINITY DUCHENNE™ trial, including longer-term safety and initial microdystrophin protein expression levels in muscle at three months.
Aug 01, 2023 04:05 pm ET
REGENXBIO Announces Participation at the 2023 Wedbush PacGrow Healthcare Conference
ROCKVILLE, Md., Aug. 1, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host one-on-one investor meetings at the 2023 Wedbush PacGrow Healthcare Conference on Tuesday, June 8, 2023.
Jul 26, 2023 07:05 am ET
REGENXBIO to Host Conference Call on August 2 to Discuss Second Quarter 2023 Financial Results and Recent Operational Highlights
ROCKVILLE, Md., July 26, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Wednesday, August 2, 2023, at 4:30 p.m. ET to discuss its financial results for the quarter ended June 30, 2023, and recent operational highlights.
Jul 24, 2023 04:05 pm ET
REGENXBIO Announces Upcoming Presentations at the American Society of Retina Specialists Annual Scientific Meeting
ROCKVILLE, Md., July 24, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced three presentations at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting, taking place in Seattle, Washington from July 28 through August 1, 2023. The presentations will highlight data for ABBV-RGX-314, an investigational one-time AAV therapeutic being developed in collaboration with AbbVie for the treatment of wet AMD, DR and other chronic retinal conditions, including new interim data from the pharmacodynamic study of ABBV-RGX-314 delivered subretinally using cGMP material
Jul 11, 2023 07:05 am ET
REGENXBIO Highlights AAV Pipeline with Interim Results from Retinal and Duchenne Programs at its Virtual Investor Day on July 11, 2023
-Interim results from Phase II AAVIATE and ALTITUDE trials of dose level 3 cohorts with short-course prophylactic steroid eye drops resulted in zero cases of intraocular inflammation
Jun 27, 2023 07:05 am ET
REGENXBIO to Host Virtual Investor Day Highlighting AAV Pipeline Programs with Upcoming Interim Trial Updates
-REGENXBIO AAV Therapeutics pipeline to be discussed by management and external experts
Jun 20, 2023 08:00 am ET
REGENXBIO and University of Pennsylvania File NAV® Technology Patent Infringement Lawsuit
ROCKVILLE, Md., June 20, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it has filed a second complaint for patent infringement against Sarepta Therapeutics, Inc. (Sarepta) arising from Sarepta's manufacture, use and imminent commercial launch of SRP-9001 for the treatment of Duchenne muscular dystrophy.
Jun 01, 2023 07:05 am ET
REGENXBIO Announces Presentation at the Jefferies Global Healthcare Conference
ROCKVILLE, Md., June 1, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present and host one-on-one investor meetings at the Jefferies Global Healthcare Conference on Thursday, June 8, 2023.
May 23, 2023 07:05 am ET
REGENXBIO Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RGX-121 Gene Therapy for Hunter Syndrome
RMAT recognizes that the preliminary clinical evidence from RGX-121, a potential one-time AAV Therapeutic, indicates the potential to address unmet medical needs for MPS II RMAT designation is for gene therapies intended to treat or cure serious condition in order to expedite the drug development and review processesCAMPSIITE™ trial is enrolling MPS II patients as part of a pivotal program that incorporates material from the NAVXpress™ platform process manufactured at the REGENXBIO Manufacturing Innovation Center and continues to support plan to file Biologics License Application in 2024 usi
May 22, 2023 07:05 am ET
REGENXBIO Announces Presentation at the Barclays Gene Editing & Therapy Summit 2023
ROCKVILLE, Md., May 22, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present in a fireside chat and panel as well as host one-on-one investor meetings at the Barclays Gene Editing & Therapy Summit 2023 on Wednesday, May 24, 2023.
May 16, 2023 05:52 pm ET
REGENXBIO Announces NAV® Technology Platform Will Support Bespoke Gene Therapy Consortium's First Rare Disease Clinical Portfolio
Research in MPS IVA led by REGENXBIO scientists moving into clinicDonation of NAV® Technology licenses will support development of gene therapies for rare diseasesROCKVILLE, Md., May 16, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that preclinical research in Mucopolysaccharidosis type IVA (MPS IVA), also known as Morquio syndrome, was selected for inclusion in the Foundation for the National Institutes of Health Accelerating Medicines Partnership® Bespoke Gene Therapy Consortium (AMP® BGTC), clinical trial portfolio. The Consortium brings together partners such as NIH
May 08, 2023 07:05 am ET
REGENXBIO to Participate in Upcoming Investor Conferences
ROCKVILLE, Md., May 8, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor conferences:
May 03, 2023 04:05 pm ET
REGENXBIO Reports First Quarter 2023 Financial Results and Recent Operational Highlights
Continued progress on '5x'25' strategy to advance five AAV Therapeutics from REGENXBIO's internal pipeline and licensed programs into pivotal-stage or commercial products by 2025Announced Updates to Eye Care Collaboration with AbbVieInvestigational gene therapy renamed ABBV-RGX-314IND sponsorship recently transferred to AbbVie for all ongoing clinical trialsExpanding sites and enrollment in ATMOSPHERE® and ASCENT™ pivotal trials using subretinal delivery; now expected to support U.S. and European regulatory submissions in late 2025 through the first half of 2026Completed enrollment in expans
May 02, 2023 04:53 pm ET
REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 26th Annual Meeting
ROCKVILLE, Md., May 2, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting, taking place in Los Angeles, California from May 16 through 20, 2023. The presentations highlight the Company's end-to-end capabilities across clinical development and research and early development.
Apr 26, 2023 04:05 pm ET
REGENXBIO to Host Conference Call on May 3 to Discuss First Quarter 2023 Financial Results and Recent Operational Highlights
ROCKVILLE, Md., April 26, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Wednesday, May 3, 2023, at 4:30 p.m. ET to discuss its financial results for the quarter ended March 31, 2023, and recent operational highlights.
Apr 18, 2023 07:05 am ET
REGENXBIO Announces Presentation at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
ROCKVILLE, Md., April 18, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will present in a fireside chat at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on Tuesday, April 25, 2023 at 9:30 a.m. ET. The conference will be held in a virtual meeting format.
Apr 11, 2023 07:05 am ET
REGENXBIO Receives FDA Fast Track Designation for RGX-202, a Novel Gene Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy
RGX-202 is a potential one-time AAV Therapeutic for the treatment of Duchenne and includes an optimized transgene for a novel microdystrophin and REGENXBIO's proprietary NAV® AAV8 vectorCommercial-scale cGMP material from the REGENXBIO Manufacturing Innovation Center to be used in the clinical trialAFFINITY DUCHENNE™ Phase I/II trial of RGX-202 is active and recruiting patients; anticipated to report initial trial data in the second half of 2023 ROCKVILLE, Md., April 11, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that the U.S. Food and Drug Administration (FDA) has gr
Mar 08, 2023 06:05 am ET
REGENXBIO to Participate in Upcoming Investor Conferences
ROCKVILLE, Md., March 8, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor conferences:
Feb 24, 2023 08:20 am ET
Additional Positive Interim Data from Phase I/II Trial of REGENXBIO'S RGX-111 for the Treatment of Severe MPS I Presented at WORLDSymposium™
RGX-111 is an investigational AAV Therapeutic for the treatment of severe MPS I that is part of REGENXBIO's clinical-stage pipeline of neurodegenerative disease programsRGX-111, a potential one-time gene therapy for MPS I, continues to be well-tolerated across two dose levels, with no drug-related serious adverse eventsNew biomarker and neurodevelopmental data continue to indicate encouraging CNS profile in patients dosed with RGX-111 Company is on track to manufacture commercial-scale cGMP material to support the continued development of RGX-111 ROCKVILLE, Md., Feb. 24, 2023 /PRNewswire/ --
Feb 21, 2023 06:05 am ET
REGENXBIO to Host Conference Call on February 28 to Discuss Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights
ROCKVILLE, Md., Feb. 21, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Tuesday, February 28, 2023, at 4:30 p.m. ET to discuss its financial results for the quarter and full year ended December 31, 2022, and recent operational highlights.
Feb 17, 2023 06:05 am ET
REGENXBIO Announces Presentations at the 19th Annual WORLDSymposium™ 2023
New interim data from Phase I/I/III trial of RGX-121 for the treatment of MPS II and Phase I/II trial of RGX-111 for the treatment of MPS I to be presentedROCKVILLE, Md., Feb. 17, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that three oral and eight poster presentations will be presented at the 19th Annual WORLDSymposium™ 2023, taking place in Orlando, Florida from February 22 through 26, 2023. The presentations include new interim results from the Phase I/II/III clinical trial of RGX-121 for the treatment of mucopolysaccharidosis type II (MPS II), also known as Hunter
Feb 11, 2023 07:40 am ET
REGENXBIO Presents Interim Data from Phase II Bridging Study Evaluating the Clinical Performance of RGX-314 Using the NAVXpress™ Manufacturing Platform Process
RGX-314 produced by the NAVXpress platform process has been well-tolerated and demonstrated a similar clinical profile to the initial adherent cell culture processNAVXpress platform process is incorporated in the two ongoing pivotal trials and is expected to be used for future commercialization of RGX-314; the two pivotal trials are expected to support BLA submission in 2024Company to host live webcast with wet AMD Key Opinion Leaders to discuss new interim Phase II bridging study data, today, Saturday, February 11, at 11:30 a.m. ETROCKVILLE, Md., Feb. 11, 2023 /PRNewswire/ -- REGENXBIO Inc.
Feb 08, 2023 06:05 am ET
REGENXBIO Announces Presentation at the Virtual SVB Securities Global Biopharma Conference
ROCKVILLE, Md., Feb. 8, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present at the SVB Securities Global Biopharma Conference on Thursday, February 16, 2023.
Feb 06, 2023 06:05 am ET
REGENXBIO Announces Presentations at the Angiogenesis, Exudation, and Degeneration 2023 Conference
ROCKVILLE, Md., Feb. 6, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that three presentations on RGX-314 will be presented at the Angiogenesis, Exudation, and Degeneration 2023 Conference taking place virtually from February 10-11, 2023. New data will be presented from a Phase II bridging study evaluating the pharmacodynamics, safety and efficacy of RGX-314 delivered subretinally using cGMP material produced by the REGENXBIO NAVXpress™ platform process to support future commercialization.
Jan 26, 2023 08:00 am ET
Pathway Development Consortium Announces Publication in Human Gene Therapy on the Application of FDA’s Accelerated Approval Pathway for AAV Gene Therapies for Patients with Duchenne Muscular Dystrophy
The Pathway Development Consortium (PDC), a public-private collaboration founded by REGENXBIO Inc. (Nasdaq: RGNX) and Solid Biosciences Inc. (Nasdaq: SLDB), today announced the publication of a peer-reviewed manuscript, Micro-dystrophin expression...
Jan 23, 2023 06:05 am ET
REGENXBIO Announces Phase I/II Trial of RGX-202, a Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy, is Active and Recruiting Patients
-  Company has initiated Phase I/II AFFINITY DUCHENNE™ trial of RGX-202 -  Company also enrolling newly active observational screening study, AFFINITY BEYOND, evaluating AAV8 antibody prevalence in boys with Duchenne -  Commercial-scale cGMP material from the REGENXBIO Manufacturing Innovation Center to be used in the clinical trial -  RGX-202 is a potential one-time AAV Therapeutic for the treatment of Duchenne and includes an optimized transgene for a novel microdystrophin and REGENXBIO's proprietary NAV® AAV8 vector
Jan 09, 2023 03:01 pm ET
REGENXBIO ANNOUNCES SENIOR LEADERSHIP PROMOTIONS
Curran Simpson has been appointed Chief Operating Officer Shiva Fritsch assumes the role of Chief Communications OfficerROCKVILLE, Md., Jan. 9, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the promotion of Curran Simpson from Chief Technology and Operations Officer to Chief Operating Officer. In addition, Shiva Fritsch has been elevated to Chief Communications Officer and will continue in her role as Chief People Officer.
Jan 03, 2023 06:05 am ET
REGENXBIO Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference
ROCKVILLE, Md., Jan. 3, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023.
Dec 21, 2022 06:05 am ET
REGENXBIO Reports Update on Advancement of Programs for CLN2 Disease
RGX-181 and RGX-381 are potential one-time AAV Therapeutics for the treatment of the CNS and ocular manifestations of CLN2 disease, the most common form of Batten diseasePatient dosed under a single-patient investigator-initiated study of RGX-181Company announces approval of CTA for RGX-381 from the UK Health Authority and plans to initiate a Phase I/II clinical trial in the first half of 2023ROCKVILLE, Md., Dec. 21, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced a comprehensive program update to outline its progress and development plans for RGX-181 and RGX-381, both bei
Dec 08, 2022 06:05 am ET
REGENXBIO Announces Completion of Dosing in the Phase I/II Trial of RGX-111 for the Treatment of Severe MPS I
RGX-111 is an investigational AAV Therapeutic for the treatment of severe MPS I that is part of REGENXBIO's clinical-stage pipeline of neurodegenerative disease programs.Expanded Cohort 2 enrollment is complete; eight patients have received RGX-111 in the trial Company intends to manufacture commercial-scale cGMP material to support the continued development of RGX-111  Company expects additional interim updates from the RGX-111 trial in the first half of 2023ROCKVILLE, Md., Dec. 8, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it has completed dosing in the expanded Coh
Nov 22, 2022 06:05 am ET
REGENXBIO to Participate in Upcoming Investor Conferences
ROCKVILLE, Md., Nov. 22, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor conferences:
Nov 03, 2022 07:05 am ET
REGENXBIO Reports Third Quarter 2022 Financial Results and Recent Operational Highlights
Continued progress on 5x25 strategy to advance five AAV Therapeutics from our internal pipeline and licensed programs into pivotal-stage or commercial products by 2025RGX-314 program for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, remains on track for first BLA filing in 2024 Enrollment ongoing in the pivotal ATMOSPHERE® and ASCENT™ clinical trials of RGX-314 for the treatment of wet AMD using subretinal deliveryPresented positive interim data from RGX-314 trials for the treatment of wet AMD - the Phase II AAVIATE® trial using suprachoroid
Nov 03, 2022 06:30 am ET
REGENXBIO Presents Positive Interim Data from and the Expansion of Phase II ALTITUDE® Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery
RGX-314 continues to be well tolerated in 50 patients from Cohorts 1-3 with no drug-related serious adverse events Patients treated with RGX-314 in Cohorts 1-3 demonstrated clinically meaningful improvements in disease severity and less disease worsening versus observation control at six months 20% of patients achieved ≥2-step DRSS improvement vs. 10% in control 54% of patients achieved any DRSS improvement vs. 20% in control 0% of patients worsened ≥2 steps vs. 20% in controlNo meaningful differences in safety outcomes at six months for patients who are NAb positivePhase II trial expanded t
Nov 02, 2022 07:05 am ET
REGENXBIO to Participate in Upcoming Investor Conferences
ROCKVILLE, Md., Nov. 2, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor conferences:
Oct 27, 2022 07:05 am ET
REGENXBIO to Host Conference Call on November 3 to Discuss Third Quarter 2022 Financial Results, Recent Operational Highlights and Interim Data from Phase II ALTITUDE® Trial of RGX-314 for the Treatme
ROCKVILLE, Md., Oct. 27, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present data from the ALTITUDE® clinical trial evaluating RGX-314 using suprachoroidal delivery for the treatment of patients with diabetic retinopathy at the Retina Society 55th Annual Scientific Meeting taking place in Pasadena, CA, from November 2-5, 2022.
Oct 04, 2022 07:05 am ET
Positive Data Presentations at AAO Annual Meeting Demonstrate Utility and Versatility of Clearside Biomedical’s Proprietary Suprachoroidal Space Platform
Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that clinical data from multiple internal and partnered...
Oct 03, 2022 07:05 am ET
REGENXBIO Announces Additional Positive Interim Data from Trials of RGX-314 for the Treatment of Wet AMD
Company announced positive interim data from and the expansion of Phase II AAVIATE® trial of RGX-314 for the treatment of wet AMD using suprachoroidal delivery RGX-314 continues to be well tolerated in 85 patients from Cohorts 1-5 with no drug-related serious adverse eventsMeaningful reduction in treatment burden at six months across all dose levels, 85% reduction in treatment burden observed at third dose level67% of patients in Cohort 4 were injection-freeNo meaningful differences in outcomes at six months for patients who are NAb positivePhase II trial expanded to include new cohort at th
Sep 27, 2022 07:05 am ET
REGENXBIO Announces Presentation at Chardan's 6th Annual Genetic Medicines Conference
ROCKVILLE, Md., Sept. 27, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present in a fireside chat at Chardan's 6th Annual Genetic Medicines Conference on Tuesday, October 4th, 2022:
Sep 26, 2022 07:05 am ET
REGENXBIO Announces Upcoming Presentations During the American Academy of Ophthalmology 2022 Annual Meeting
Company to host conference call on Monday, October 3rd at 8:30 a.m. ET to discuss new, interim data from the ongoing Phase II AAVIATE® trial
Sep 06, 2022 07:05 am ET
REGENXBIO to Participate in Upcoming Investor Conferences
ROCKVILLE, Md., Sept. 6, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor conferences:
Aug 31, 2022 07:05 am ET
REGENXBIO Presents Additional Positive Interim Data from the Phase I/II/III CAMPSIITE™ Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome) at the Society for the Study of Inborn Errors of M
-       New data in Cohort 3 using pivotal program dose level demonstrates largest median reduction in CSF GAGs, continuing to approach normal levels at 48 weeks-       RGX-121, a one-time gene therapy for MPS II, continues to be well-tolerated with no drug-related SAEs across three dose levels-       Positive interim data supports recently announced plan to file Biologics License Application in 2024 using the accelerated approval pathway
Aug 23, 2022 07:05 am ET
REGENXBIO Announces Presentations at the Society for the Study of Inborn Errors of Metabolism Annual Symposium
ROCKVILLE, Md., Aug. 23, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the Society for the Study of Inborn Errors of Metabolism Annual Symposium, taking place from August 30 through September 2, 2022, in Freiburg, Germany. The presentations will highlight new data from the Phase I/II/III CAMPSIITE™ trial of RGX-121, an investigational one-time AAV Therapeutic for the treatment of Mucopolysaccharidosis Type II (MPS II), also known as Hunter Syndrome, and an encore data presentation for RGX-111, an investigational one-time AAV Therapeutic for the treatment
Aug 10, 2022 07:05 am ET
REGENXBIO Announces Presentation at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
ROCKVILLE, Md., Aug. 10, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference on Wednesday, August 17th, 2022:
Aug 03, 2022 04:05 pm ET
REGENXBIO Reports Second Quarter 2022 Financial Results and Recent Operational Highlights
RGX-314 program for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, remains on track for first BLA filing in 2024 Enrollment ongoing in the pivotal ATMOSPHERE® and ASCENT™ clinical trials of RGX-314 for the treatment of wet AMD using subretinal deliveryCompleted enrollment in Cohort 5 of the AAVIATE® trial of RGX-314 for the treatment of wet AMD using suprachoroidal deliveryCompleted enrollment in ALTITUDE® trial of RGX-314 for the treatment of diabetic retinopathy using suprachoroidal delivery AFFINITY DUCHENNE™ Phase I/II trial of RGX-202 re
Aug 03, 2022 07:05 am ET
REGENXBIO Announces Intention to File a Biologics License Application Using the Accelerated Approval Pathway for RGX-121, an AAV Therapeutic for the Treatment of MPS II
FDA will consider an accelerated approval pathway for RGX-121; BLA filing expected in 2024 Pivotal program is active and enrolling patients RGX-121 is a potential first-in-class, one-time gene therapy for the treatment of MPS IIInternal cGMP manufacturing process expected to support BLAROCKVILLE, Md., Aug. 3, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced its intention to file a Biologics License Application (BLA) in 2024 using the FDA's accelerated approval pathway for RGX-121 for the treatment of Mucopolysaccharidosis Type II (MPS II), also known as Hunter Syndrome. The
Aug 01, 2022 07:05 am ET
REGENXBIO to Host Conference Call on August 3 to Discuss Second Quarter 2022 Financial Results and Recent Operational Highlights
ROCKVILLE, Md., Aug. 1, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Wednesday, August 3, 2022, at 4:30 p.m. ET to discuss its financial results for the quarter ended June 30, 2022, and recent operational highlights.
Jul 07, 2022 08:00 am ET
Eyenovia Announces Appointments of Dr. Ellen Strahlman and Dr. Ram Palanki as New and Independent Members of its Board of Directors
Eyenovia, Inc. (Nasdaq: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of late-stage microdose array print (MAP™) therapeutics, today announced that it has appointed Dr. Ellen Strahlman and Dr. Ram Palanki as new and...
Jun 09, 2022 02:45 pm ET
REGENXBIO Opens State-of-the-Art Gene Therapy Manufacturing Facility
In-house facility to produce NAV Technology-based AAV gene therapies at 2,000 liters scale$65 million invested in new facility, enabling end-to-end control of gene therapy manufacturing in Montgomery County, MarylandROCKVILLE, Md., June 9, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today is celebrating the opening of its new Manufacturing Innovation Center gene therapy manufacturing facility.
Jun 07, 2022 07:05 am ET
Jennifer Zachary Joins REGENXBIO Board of Directors
ROCKVILLE, Md., June 7, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the appointment of Jennifer Zachary to its Board of Directors, effective June 3, 2022. Ms. Zachary will serve as a member of REGENXBIO's Audit Committee and brings 20 years of legal and regulatory experience working in the pharmaceutical and medical device industries.
May 04, 2022 04:05 pm ET
REGENXBIO Reports First Quarter 2022 Financial Results and Recent Operational Highlights
ROCKVILLE, Md., May 4, 2022 /PRNewswire/ --
May 04, 2022 07:05 am ET
REGENXBIO to Participate in Upcoming Investor Conferences
ROCKVILLE, Md., May 4, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor conferences:
May 03, 2022 07:05 am ET
REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting
ROCKVILLE, Md., May 3, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting, taking place virtually and in Washington, D.C. from May 16 through 19, 2022. The presentations highlight the Company's end-to-end capabilities across research and early development, clinical development and manufacturing.  
Apr 27, 2022 07:05 am ET
REGENXBIO to Host Conference Call on May 4 to Discuss First Quarter 2022 Financial Results and Recent Operational Highlights
ROCKVILLE, Md., April 27, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Wednesday, May 4, 2022, at 4:30 p.m. ET to discuss its financial results for the quarter ended March 31, 2022, and recent operational highlights.
Apr 20, 2022 07:05 am ET
REGENXBIO Announces Presentation at Chardan's 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
ROCKVILLE, Md., April 20, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will present in a fireside chat at Chardan's 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on Tuesday, April 26, 2022 at 8:30 a.m. ET. The conference will be held in a virtual meeting format.
Mar 09, 2022 06:05 am ET
REGENXBIO to Participate in Upcoming Investor Conferences
ROCKVILLE, Md., March 9, 2022 /PRNewswire/ --  REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor conferences:
Mar 01, 2022 03:05 pm ET
REGENXBIO Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Operational Highlights
ROCKVILLE, Md., March 1, 2022 /PRNewswire/ --
Feb 22, 2022 03:05 pm ET
REGENXBIO to Host Conference Call on March 1 to Discuss Fourth Quarter and Full-Year 2021 Financial Results and Recent Operational Highlights
ROCKVILLE, Md., Feb. 22, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Tuesday, March 1, 2022, at 4:30 p.m. ET to discuss its financial results for the quarter and full-year ended December 31, 2021, and recent operational highlights.
Feb 12, 2022 11:20 am ET
REGENXBIO Presents Positive Interim Data from Phase II ALTITUDE™ Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery
ROCKVILLE, Md., Feb. 12, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced additional positive interim data from the ongoing Phase II ALTITUDE™ trial of RGX-314 for the treatment of diabetic retinopathy (DR) without center-involved diabetic macular edema (CI-DME) using in-office suprachoroidal delivery. The data is being presented at the Angiogenesis, Exudation, and Degeneration 2022 conference by Michael A. Klufas, M.D., Retina Service, Wills Eye Hospital, Assistant Professor of Ophthalmology, Thomas Jefferson University. RGX-314 is being investigated as a potential one-tim
Feb 09, 2022 10:36 am ET
REGENXBIO Presents Positive Initial Data from Phase I/II Trial of RGX-111 for the Treatment of Severe MPS I at 18th Annual WORLDSymposium™ 2022
ROCKVILLE, Md., Feb. 9, 2022 /PRNewswire/ --
Feb 09, 2022 10:12 am ET
REGENXBIO Presents Additional Positive Interim Data from Phase I/II Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome) at 18th Annual WORLDSymposium™ 2022
ROCKVILLE, Md., Feb. 9, 2022 /PRNewswire/ --
Feb 08, 2022 06:05 am ET
REGENXBIO Announces Presentations at the 11th Annual SVB Leerink Global Healthcare Conference
ROCKVILLE, Md., Feb. 8, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will present in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 16, 2022 at 8:40 a.m. ET. The conference will be held in a virtual meeting format.
Feb 04, 2022 06:05 am ET
REGENXBIO Announces Presentations at the Angiogenesis, Exudation, and Degeneration 2022 Conference
ROCKVILLE, Md., Feb. 4, 2022 /PRNewswire/ -- 
Jan 31, 2022 06:05 am ET
REGENXBIO Announces Presentations at the 18th Annual WORLDSymposium™ 2022
ROCKVILLE, Md., Jan. 31, 2022 /PRNewswire/ -- 
Jan 10, 2022 06:05 am ET
REGENXBIO Announces Initiation of Second Pivotal Trial in RGX-314 Clinical Program for the Treatment of Wet AMD Using Subretinal Delivery
ROCKVILLE, Md., Jan. 10, 2022 /PRNewswire/ --
Jan 06, 2022 06:05 am ET
REGENXBIO Announces FDA Clearance of IND for Clinical Trial of RGX-202, a Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy
ROCKVILLE, Md., Jan. 6, 2022 /PRNewswire/ --
Nov 22, 2021 06:00 am ET
REGENXBIO Announces Orphan Drug Designation Granted to RGX-202, a Novel Gene Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy
ROCKVILLE, Md., Nov. 22, 2021 /PRNewswire/ --
Nov 12, 2021 03:32 pm ET
REGENXBIO Presents Additional Positive Interim Data from Trials of RGX-314 in Wet AMD and Diabetic Retinopathy Using Suprachoroidal Delivery at AAO 2021
ROCKVILLE, Md., Nov. 12, 2021 /PRNewswire/ --
Nov 09, 2021 03:05 pm ET
REGENXBIO Announces Closing of Eye Care Collaboration Agreement with AbbVie
ROCKVILLE, Md., Nov. 9, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the closing of its Collaboration and License Agreement with AbbVie to develop and commercialize RGX-314, a potential one-time gene therapy for the treatment of wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other chronic retinal diseases. As previously announced on September 13, 2021, under the terms of the agreement, REGENXBIO will receive an upfront payment from AbbVie of $370 million with the potential for REGENXBIO to receive up to $1.38 billion in additional developm
Nov 08, 2021 06:00 am ET
REGENXBIO to Participate in Upcoming Investor Conferences
ROCKVILLE, Md., Nov. 8, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences, which will each be held in a virtual meeting format:
Nov 05, 2021 07:00 am ET
REGENXBIO Announces RGX-314 Data Presentation at the American Academy of Ophthalmology 2021 Annual Meeting
ROCKVILLE, Md., Nov. 5, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that data from the RGX-314 clinical trials will be presented in an oral presentation at the American Academy of Ophthalmology 2021 Annual Meeting taking place in New Orleans, LA from November 12 to 15, 2021. RGX-314 is a potential one-time gene therapy in clinical development for the treatment of wet age-related macular degeneration (wet AMD) and diabetic retinopathy.
Nov 02, 2021 04:05 pm ET
REGENXBIO Reports Third Quarter 2021 Financial Results and Operational Highlights
ROCKVILLE, Md., Nov. 2, 2021 /PRNewswire/ --
Nov 02, 2021 07:30 am ET
Pathway Development Consortium Releases Draft White Paper to Facilitate AAV Gene Therapy Development
The Pathway Development Consortium (PDC), a new public-private collaboration founded by REGENXBIO Inc. (Nasdaq: RGNX) and Solid Biosciences Inc. (Nasdaq: SLDB), today announced the publication of a draft white paper, Draft Framework for AAV Gene...
Oct 26, 2021 04:05 pm ET
REGENXBIO to Host Conference Call on November 2 to Discuss Third Quarter 2021 Financial Results and Recent Operational Highlights
ROCKVILLE, Md., Oct. 26, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Tuesday, November 2, 2021, at 4:30 p.m. ET to discuss its financial results for the quarter ended September 30, 2021, and recent operational highlights.
Oct 09, 2021 11:23 am ET
REGENXBIO Presents Positive Initial Data from Phase II ALTITUDE™ Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery at American Society of Retina Specialists Annu
ROCKVILLE, Md., Oct. 9, 2021 /PRNewswire/ --
Oct 01, 2021 03:47 pm ET
REGENXBIO Presents Positive Initial Data from Phase II AAVIATE® Trial of RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery and Provides Trial Update at Retina Society 54th Annual Scie
ROCKVILLE, Md., Oct. 1, 2021 /PRNewswire/ --
Oct 01, 2021 07:05 am ET
REGENXBIO Announces RGX-314 Data Presentations at American Society of Retina Specialists Annual Meeting
ROCKVILLE, Md., Oct. 1, 2021 /PRNewswire/ --
Sep 27, 2021 07:05 am ET
REGENXBIO Announces RGX-314 Data Presentations at Retina Society 54th Annual Scientific Meeting and KOL Conference Call
ROCKVILLE, Md., Sept. 27, 2021 /PRNewswire/ --
Sep 13, 2021 06:30 am ET
AbbVie and REGENXBIO Announce Eye Care Collaboration
NORTH CHICAGO, Ill. and ROCKVILLE, Md., Sept. 13, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) and REGENXBIO Inc. (Nasdaq: RGNX) today announced a partnership to develop and commercialize RGX-314, a potential one-time gene therapy for the treatment of wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other chronic retinal diseases. RGX-314 is currently being evaluated in patients with wet AMD in a pivotal trial utilizing subretinal delivery, and in patients with wet AMD and DR in two separate Phase II clinical trials utilizing in-office suprachoroidal delivery. 
Sep 07, 2021 04:05 pm ET
REGENXBIO to Participate in Upcoming Investor Conferences
ROCKVILLE, Md., Sept. 7, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences, which will each be held in a virtual meeting format:
Sep 07, 2021 07:05 am ET
Dr. Jean Bennett and George Migausky Join REGENXBIO Board of Directors
ROCKVILLE, Md., Sept. 7, 2021 /PRNewswire/ -- 
Aug 09, 2021 04:05 pm ET
REGENXBIO Reports Second Quarter 2021 Financial Results and Operational Highlights
ROCKVILLE, Md., Aug. 9, 2021 /PRNewswire/ --
Aug 02, 2021 04:05 pm ET
REGENXBIO to Host Conference Call on August 9 to Discuss Second Quarter 2021 Financial Results and Recent Operational Highlights
ROCKVILLE, Md., Aug. 2, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Monday, August 9, 2021, at 4:30 p.m. ET to discuss its financial results for the quarter ended June 30, 2021, and recent operational highlights.
Jun 09, 2021 07:05 am ET
REGENXBIO to Participate in Upcoming Investor Conferences
ROCKVILLE, Md., June 9, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following June investor conferences, which will each be held in a virtual meeting format:
Feb 24, 2021 03:05 pm ET
REGENXBIO to Participate in Upcoming Investor Conferences
ROCKVILLE, Md., Feb. 24, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following March investor conferences, which will each be held in a virtual meeting format:
Feb 22, 2021 03:05 pm ET
REGENXBIO to Host Conference Call on March 1 to Discuss Fourth Quarter and Full-Year 2020 Financial Results and Recent Operational Highlights
ROCKVILLE, Md., Feb. 22, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Monday, March 1, 2021, at 4:30 p.m. ET to discuss its financial results for the quarter and full-year ended December 31, 2020, and recent operational highlights.
Feb 16, 2021 06:05 am ET
REGENXBIO Announces Additional Positive Interim Phase I/IIa and Long-Term Follow-Up Data of RGX-314 for the Treatment of Wet AMD
ROCKVILLE, Md., Feb. 16, 2021 /PRNewswire/ --
Feb 08, 2021 01:29 pm ET
REGENXBIO Presents Additional Positive Interim Data from Phase I/II Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome) at 17th Annual WORLDSymposium™ 2021
ROCKVILLE, Md., Feb. 8, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that additional positive interim data from a total of eight patients in Cohorts 1 and 2 of the ongoing Phase I/II trial of RGX-121 for the treatment of patients up to 5 years old diagnosed with Mucopolysaccharidosis Type II (MPS II), also known as Hunter Syndrome, will be presented at the 17th Annual WORLDSymposium™.
Feb 05, 2021 06:05 am ET
REGENXBIO Announces Presentations at the Angiogenesis, Exudation, and Degeneration 2021 Conference
ROCKVILLE, Md., Feb. 5, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that two oral presentations will be presented at the Angiogenesis, Exudation, and Degeneration 2021 conference taking place virtually from February 12 to 13, 2021.
Feb 01, 2021 06:05 am ET
REGENXBIO Announces Presentations at the 17th Annual WORLDSymposium™ 2021
ROCKVILLE, Md., Feb. 1, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that three oral and nine poster presentations will be presented at the 17th Annual WORLDSymposium™, taking place virtually from February 8 through 12, 2021. The oral presentations include interim results from the Phase I/II clinical trial of RGX-121 for the treatment of mucopolysaccharidosis type II (MPS II).
Jan 12, 2021 03:05 pm ET
REGENXBIO Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares
ROCKVILLE, Md., Jan. 12, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the closing of its previously announced underwritten public offering of 4,260,000 shares of its common stock at a price to the public of $47.00 per share, as well as the exercise in full of the underwriters' option to purchase 639,000 additional shares at the public offering price. Including the option exercise, the total gross proceeds to REGENXBIO are expected to be approximately $230.3 million, before deducting the underwriting discounts and commissions and estimated offering expenses.
Jan 11, 2021 06:05 am ET
REGENXBIO to Present at the 39th Annual J.P. Morgan Healthcare Conference
ROCKVILLE, Md., Jan. 11, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021 at 11:40 a.m. ET. The conference will be held in a virtual meeting format.
Jan 08, 2021 06:05 am ET
REGENXBIO Announces Pricing Of Public Offering Of Common Stock
ROCKVILLE, Md., Jan. 8, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the pricing of an underwritten public offering of 4,260,000 shares of its common stock at the price of $47.00 per share before underwriting discounts and commissions. The gross proceeds to REGENXBIO from the offering, before deducting the underwriting discounts and commissions and other offering expenses payable by REGENXBIO, are expected to be approximately $200.2 million. This offering is expected to close on January 12, 2021, subject to customary closing conditions. In addition, REGENXBIO has grante
Jan 06, 2021 03:01 pm ET
REGENXBIO Announces Proposed Public Offering Of Common Stock
ROCKVILLE, Md., Jan. 6, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it intends to offer and sell, subject to market conditions, $175,000,000 of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. In addition, REGENX
Jan 05, 2021 03:05 pm ET
REGENXBIO Announces Update on RGX-314 and Pivotal Program for the Treatment of Wet AMD and New Gene Therapy Program for the Treatment of Duchenne Muscular Dystrophy
ROCKVILLE, Md., Jan. 5, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today provided an update on the RGX-314 programs, including the announcement that the pivotal program for RGX-314 for the treatment of wet age-related macular degeneration (wet AMD) is now active. In addition, REGENXBIO announced a new program, RGX-202, a novel, potentially best-in-class, one-time gene therapy for the treatment of Duchenne Muscular Dystrophy (DMD).
Dec 22, 2020 03:19 pm ET
REGENXBIO Announces Agreement to Monetize Portion of Zolgensma® Royalties for $200 Million
ROCKVILLE, Md., Dec. 22, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it has entered into an agreement to sell a portion of the royalty rights due to REGENXBIO from Novartis Gene Therapies from the net sales of Zolgensma® to entities managed by Healthcare Royalty Management, LLC (HCR) for a gross purchase price of $200 million. This transaction provides immediate, non-dilutive capital to REGENXBIO
Dec 10, 2020 06:05 am ET
REGENXBIO Announces Dosing of First Patient in Phase II ALTITUDE™ Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery
ROCKVILLE, Md., Dec. 10, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that the first patient has been dosed in ALTITUDE, a Phase II trial to evaluate the suprachoroidal delivery of RGX-314 using the SCS Microinjector for the treatment of diabetic retinopathy (DR).
Dec 09, 2020 06:05 am ET
REGENXBIO Announces Positive Interim Data and Update for Phase I/II Trial of RGX-121 for the Treatment of MPS II
ROCKVILLE, Md., Dec. 8, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced interim data from Cohorts 1 and 2 of the ongoing Phase I/II trial of RGX-121 for the treatment of patients up to 5 years old diagnosed with Mucopolysaccharidosis Type II (MPS II). In addition, REGENXBIO announced plans to evaluate a higher dose of RGX-121 in a third cohort of patients at an increased dose of 2.0x1011 GC/g brain mass.
Dec 01, 2020 06:05 am ET
REGENXBIO Announces Dosing of First Patient in Phase I/II Trial of RGX-111 for the Treatment of Mucopolysaccharidosis Type I
ROCKVILLE, Md., Dec. 1, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that the first patient has been dosed in the Phase I/II trial of RGX-111 for the treatment of Mucopolysaccharidosis Type I (MPS I). RGX-111 is an investigational one-time gene therapy designed to deliver the α-l-iduronidase (IDUA) gene directly to the central nervous system (CNS) using the NAV AAV9 vector.
Nov 23, 2020 03:05 pm ET
REGENXBIO to Present at Upcoming Investor Conferences
ROCKVILLE, Md., Nov. 23, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced it will present at the following December investor conferences, which will each be held in a virtual meeting format:
Nov 10, 2020 06:00 am ET
REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2020 Annual Meeting
ROCKVILLE, Md., Nov. 10, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that two oral presentations will be presented at the American Academy Ophthalmology (AAO) 2020 Annual Meeting, taking place November 13-15, 2020 in a virtual format.
Nov 05, 2020 03:05 pm ET
REGENXBIO to Present at Upcoming Investor Conferences
ROCKVILLE, Md., Nov. 5, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced it will present at the following November investor conferences, which will each be held in a virtual meeting format:
Nov 04, 2020 03:05 pm ET
REGENXBIO Reports Third Quarter 2020 Financial Results and Operational Highlights
ROCKVILLE, Md., Nov. 4, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced financial results for the quarter ended September 30, 2020, and recent operational highlights.
Oct 28, 2020 04:05 pm ET
REGENXBIO To Host Conference Call on November 4 to Discuss Third Quarter 2020 Financial Results and Recent Operational Highlights
ROCKVILLE, Md., Oct. 28, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will host a conference call on Wednesday, November 4, 2020, at 4:30 p.m. ET to discuss its financial results for the quarter ended September 30, 2020, and recent operational highlights.
Oct 27, 2020 07:00 am ET
REGENXBIO to Receive $80.0 Million Milestone Payment from Novartis AG
ROCKVILLE, Md., Oct. 27, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will receive a milestone payment of $80.0 million from Novartis AG based upon the achievement of $1.0 billion in cumulative net sales of Zolgensma. REGENXBIO expects to recognize this revenue in the third quarter of 2020.
Aug 06, 2020 04:05 pm ET
REGENXBIO Reports Second Quarter 2020 Financial Results and Operational Highlights
ROCKVILLE, Md., Aug. 6, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced financial results for the quarter ended June 30, 2020, and recent operational highlights.
Aug 04, 2020 07:00 am ET
REGENXBIO Announces Additional Positive Interim Phase I/IIa Trial Update and Program Updates for RGX-314 for the Treatment of Wet AMD
ROCKVILLE, Md., Aug. 4, 2020 /PRNewswire/ --
Jul 30, 2020 04:05 pm ET
REGENXBIO To Host Conference Call on August 6 to Discuss Second Quarter 2020 Financial Results and Recent Operational Highlights
ROCKVILLE, Md., July 30, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will host a conference call on Thursday, August 6, 2020, at 4:30 p.m. ET to discuss its financial results for the quarter ended June 30, 2020, and recent operational highlights.
Jul 08, 2020 07:05 am ET
REGENXBIO Provides Update on Progress of Clinical Programs for Rare Genetic Neurodegenerative Diseases
ROCKVILLE, Md., July 8, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it has completed dosing of three patients in Cohort 2 of the Company's Phase I/II study of RGX-121 for the treatment of Mucopolysaccharidosis Type II (MPS II) and reported encouraging data under a single-patient investigator-initiated Investigational New Drug (IND) application for RGX-111 for the treatment of Mucopolysaccharidosi
Jun 10, 2020 07:30 am ET
REGENXBIO to Present at the Raymond James Human Health Innovation Conference
ROCKVILLE, Md., June 10, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced it will present at the Raymond James Human Health Innovation Conference on Wednesday, June 17, 2020, at 3:00 p.m. ET. The conference will be held in a virtual meeting format.
May 07, 2020 04:01 pm ET
REGENXBIO Reports First Quarter 2020 Financial Results and Operational Highlights
ROCKVILLE, Md., May 7, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced financial results for the quarter ended March 31, 2020, and recent operational highlights.
Apr 28, 2020 05:38 pm ET
REGENXBIO Announces Presentations at the American Society of Gene and Cell Therapy's 23rd Annual Meeting
ROCKVILLE, Md., April 28, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that three oral presentations, and several poster presentations, will be presented at the American Society of Gene and Cell Therapy's 23rd Annual Meeting taking place May 12-15, 2020 in virtual format. Presentations and posters will be available at www.asgct.org.
Apr 22, 2020 06:30 am ET
REGENXBIO Announces Additional Positive Long-term and Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD
ROCKVILLE, Md., April 22, 2020 /PRNewswire/ --
Mar 31, 2020 04:05 pm ET
REGENXBIO and Ultragenyx Announce New License Agreement for Use of NAV® Technology Platform for the Treatment of Rare Metabolic Disorder
REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV Technology Platform, and Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE),...
Mar 31, 2020 04:05 pm ET
REGENXBIO and Ultragenyx Announce New License Agreement for Use of NAV® Technology Platform for the Treatment of Rare Metabolic Disorder
ROCKVILLE, Md. and NOVATO, Calif., March 31, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV Technology Platform, and Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare diseases, today announced a new exclusive, worldwide license agreement, extending the companies' existing gene therapy partnership.
Nov 05, 2019 03:05 pm ET
REGENXBIO Reports Third Quarter 2019 Financial and Operating Results and Recent Operational Highlights
ROCKVILLE, Md., Nov. 5, 2019 /PRNewswire/ --
Oct 30, 2019 07:05 am ET
Clearside Biomedical Announces Option Exercise by REGENXBIO for Global License for Use of SCS Microinjector™ in AAV Gene Therapy Delivery
Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that REGENXBIO Inc. (Nasdaq:...
Oct 29, 2019 07:00 am ET
REGENXBIO To Host Conference Call on November 5 to Discuss Third Quarter 2019 Financial Results and Recent Operational Highlights
ROCKVILLE, Md., Oct. 29, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will host a conference call on Tuesday, November 5, 2019, at 4:30 p.m. ET to discuss its financial results for the quarter ended September 30, 2019, and recent operational highlights.
Oct 17, 2019 07:00 am ET
REGENXBIO Announces Presentations at the European Society of Gene & Cell Therapy 27th Annual Congress
ROCKVILLE, Md., Oct. 17, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced the presentation of two posters at the European Society of Gene & Cell Therapy (ESGCT) 27th Annual Congress in Barcelona, Spain, taking place from October 22 to 25, 2019.
Oct 11, 2019 07:15 pm ET
REGENXBIO Announces Additional Positive Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting
ROCKVILLE, Md., Oct. 11, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced interim data from the ongoing Phase I/IIa trial of RGX-314 for the treatment of wet age-related macular degeneration (wet AMD). The results were presented by Jeffrey S. Heier, M.D., Co-President and Director of Retina Research at Ophthalmic Consultants of Boston and primary investigator for the trial, in a podium presentation at the
Sep 30, 2019 07:00 am ET
REGENXBIO to Present at The Chardan 3rd Annual Genetic Medicines Conference
ROCKVILLE, Md., Sept. 30, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will present at the Chardan 3rd Annual Genetic Medicines Conference on Monday, October 7, 2019, at The Westin New York Grand Central, NY:
Sep 04, 2019 07:00 am ET
REGENXBIO Announces Exclusive Worldwide Option and License Agreement with Clearside Biomedical for Evaluation of In-Office Delivery Platform for RGX-314
ROCKVILLE, Md. and ALPHARETTA, Ga., Sept. 4, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, and Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, today announced an option and license agreement for exclusive worldwide rights to Clearside's proprietary, in-office SCS Mi
Aug 28, 2019 04:05 pm ET
REGENXBIO to Present at Upcoming Investor Conferences
ROCKVILLE, Md., Aug. 28, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will present at the following September investor conferences:
Aug 27, 2019 07:00 am ET
REGENXBIO to Present Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting in October
ROCKVILLE, Md., Aug. 27, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that an interim trial update from the RGX-314 Phase I/IIa clinical trial for the treatment of wet age-related macular degeneration (wet AMD) will be reported during a presentation at the Retina Subspecialty Day program of the American Academy of Ophthalmology (AAO) 2019 Annual Meeting in San Francisco, CA. The results will be present
Aug 07, 2019 04:05 pm ET
REGENXBIO Reports Second Quarter 2019 Financial and Operating Results and Additional Positive Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD
ROCKVILLE, Md., Aug. 7, 2019 /PRNewswire/ --
Jul 31, 2019 07:07 am ET
REGENXBIO Announces New License Agreement with Pfizer for the Treatment of Friedreich's Ataxia Using NAV® AAV9 Vector
ROCKVILLE, Md., July 31, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV Technology Platform, today announced it entered into a license agreement with Pfizer Inc.
Jul 30, 2019 04:05 pm ET
REGENXBIO To Host Conference Call on August 7 to Discuss Second Quarter 2019 Financial Results and Recent Operational Highlights
ROCKVILLE, Md., July 30, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will host a conference call on Wednesday, August 7, 2019, at 4:30 p.m. ET to discuss its financial results for the quarter ended June 30, 2019, and recent operational highlights.
Jul 24, 2019 04:10 pm ET
REGENXBIO Expands Pipeline Using NAV Vectors to Deliver Therapeutic Antibodies for the Treatment of Hereditary Angioedema and Neurodegenerative Diseases
ROCKVILLE, Md., July 24, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced an expansion of its pipeline to include novel treatments for hereditary angioedema (HAE) and neurodegenerative diseases, including tauopathies, using NAV Vectors to deliver therapeutic antibodies.
Jul 24, 2019 04:05 pm ET
REGENXBIO and Neurimmune Announce Collaboration to Develop Vectorized Antibodies for the Treatment of Neurodegenerative Diseases
ROCKVILLE, Md. and ZURICH, July 24, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform and Neurimmune AG, a leading clinical-stage Swiss biotech company translating human immune memory into antibody therapeutics, today announced an exclusive license, development and commercialization agreement to discover and develop novel AAV gene therapies using NAV Vectors to deliver human antibodies against targets implicated in chro
May 24, 2019 01:14 pm ET
REGENXBIO Announces First FDA Approval of a Gene Therapy Based on Its Proprietary NAV® Technology Platform
ROCKVILLE, Md., May 24, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced the first U.S. Food and Drug Administration (FDA) approval of a gene therapy that leverages REGENXBIO's proprietary NAV Technology Platform, Novartis AG's ZOLGENSMA® (onasemnogene abeparvovec-xioi; AVXS-101). ZOLGENSMA was approved by the FDA as a one-time infusion for pediatric patients with spinal muscular atrophy (SMA) who are less
May 15, 2019 07:00 am ET
REGENXBIO to Launch New Manufacturing Facility for NAV Technology-based AAV Gene Therapies
ROCKVILLE, Md., May 15, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced its plan to construct a current good manufacturing practice (cGMP) production facility, to be located in Rockville, Maryland. The new cGMP production facility will be integrated into REGENXBIO's previously announced new 132,000 square foot headquarters, for which construction is currently underway, and will allow for production of NAV
May 08, 2019 07:00 am ET
REGENXBIO to Present at the Bank of America Merrill Lynch 2019 Healthcare Conference
ROCKVILLE, Md., May 8, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced it will present at the Bank of America Merrill Lynch 2019 Healthcare Conference on Wednesday, May 15, 2019, at the Encore Wynn Hotel, Las Vegas, NV:
May 07, 2019 04:05 pm ET
REGENXBIO Reports First Quarter 2019 Financial and Operating Results and Additional Positive Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD
ROCKVILLE, Md., May 7, 2019 /PRNewswire/ --
Apr 30, 2019 07:00 am ET
REGENXBIO to Host Conference Call on May 7 to Discuss First Quarter 2019 Financial Results and Recent Operational Highlights
ROCKVILLE, Md., April 30, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will host a conference call on Tuesday, May 7, 2019, at 4:30 p.m. ET to discuss its financial results for the quarter ended March 31, 2019, and recent operational highlights.
Apr 17, 2019 07:00 am ET
REGENXBIO Appoints Dr. Steve Pakola as Chief Medical Officer
ROCKVILLE, Md., April 17, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced the appointment of Steve Pakola, M.D., as its Senior Vice President and Chief Medical Officer. Dr. Pakola will report to Kenneth T. Mills, REGENXBIO's President and Chief Executive Officer.
Apr 15, 2019 04:05 pm ET
REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2019 Annual Meeting
ROCKVILLE, Md., April 15, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced the presentation of four posters at the American Society of Gene & Cell Therapy (ASGCT) 2019 Annual Meeting in Washington, D.C., from April 29 to May 2, 2019.
Mar 26, 2019 07:15 am ET
New Research Coverage Highlights UnitedHealth Group, Ultragenyx Pharmaceutical, Navistar International, REGENXBIO, Par Pacific, and Athenex — Consolidated Revenues, Company Growth, and Expectations fo
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of UnitedHealth Group Incorporated (NYSE:UNH), Ultragenyx Pharmaceutical Inc....
Mar 06, 2019 06:00 am ET
REGENXBIO to Participate in Upcoming Investor Conferences
ROCKVILLE, Md., March 6, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will participate in the following March investor conferences:
Feb 27, 2019 03:05 pm ET
REGENXBIO Reports Fourth Quarter and Full-Year 2018 Financial Results and Recent Operational Highlights
ROCKVILLE, Md., Feb. 27, 2019 /PRNewswire/ --
Feb 20, 2019 06:00 am ET
REGENXBIO to Host Conference Call on February 27 to Discuss Fourth Quarter and Full-Year 2018 Financial Results and Recent Operational Highlights
ROCKVILLE, Md., Feb. 20, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will host a conference call on Wednesday, February 27, 2019, at 4:30 p.m. ET to discuss its financial results for the quarter and full-year ended December 31, 2018, and recent operational highlights.
Feb 14, 2019 06:00 am ET
REGENXBIO to Host RGX-314 Program Analyst and Investor Event with Leading Retina Specialists
ROCKVILLE, Md., Feb. 14, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, will host an analyst and investor event focused on its ophthalmology program, including its lead product candidate RGX-314, on Thursday, February 21, 2019, from 9:00 a.m. to 12:00 p.m. EST in New York City. A live webcast will be available on the company's website.
Feb 04, 2019 07:20 am ET
Market Trends Toward New Normal in Keysight Technologies, Alamos Gold, ADT, SecureWorks, REGENXBIO, and Tetra Technologies — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Keysight Technologies Inc. (NYSE:KEYS), Alamos Gold Inc. (NYSE:AGI), ADT...
Jan 31, 2019 06:00 am ET
REGENXBIO Receives Rare Pediatric Disease Designation for RGX-181 Gene Therapy for the Treatment of CLN2 Form of Batten Disease
ROCKVILLE, Md., Jan. 31, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease Designation to RGX-181. RGX-181 is a one-time treatment candidate for late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease, one of the most common forms of Batten disease caused by mutations in the tripeptidyl peptidase 1 (TPP1) gene. In additio
Jan 04, 2019 06:00 am ET
REGENXBIO to Present at the 37th Annual J.P. Morgan Healthcare Conference
ROCKVILLE, Md., Jan. 4, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will present at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019 at 4:30 p.m. PST at the Westin St. Francis, San Francisco.
Jan 03, 2019 03:05 pm ET
REGENXBIO Reports Continued Progress Across Programs in Year-End 2018 Corporate Update
ROCKVILLE, Md., Jan. 3, 2019 /PRNewswire/ -- 
Nov 26, 2018 08:36 am ET
Rocket Pharmaceuticals and REGENXBIO Announce New License Agreement for the Treatment of Danon Disease Using NAV AAV9 Vector
Rocket Pharmaceuticals, Inc. (Nasdaq:RCKT), a leading U.S.-based multi-platform gene therapy company, and REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced an exclusive, worldwide license agreement for Rocket to develop and commercialize gene therapy treatments for Danon disease using REGENXBIO’s NAV AAV9 vector, as well as exclusive options for two additional NAV AAV vec
Nov 26, 2018 07:36 am ET
REGENXBIO and Rocket Pharmaceuticals Announce New License Agreement for the Treatment of Danon Disease Using NAV AAV9 Vector
ROCKVILLE, Md. and NEW YORK, Nov. 26, 2018 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, and Rocket Pharmaceuticals, Inc. (Nasdaq: RCKT), a leading U.S.-based multi-platform gene therapy company, today announced an exclusive, worldwide license agreement for Rocket to develop and commercialize gene therapy treatments for Danon disease using REGENXBIO's NAV AAV9 vector, as well as exclusive options for two additional NAV AAV
Nov 14, 2018 06:00 am ET
FDA Grants Orphan Drug Designation To RGX-181 Gene Therapy For The Treatment Of CLN2 Form Of Batten Disease
ROCKVILLE, Md., Nov. 14, 2018 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to RGX-181, a one-time treatment candidate for late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease, one of the most common forms of Batten disease caused by mutations in the tripeptidyl peptidase 1 (TPP1) gene.
Nov 12, 2018 09:00 am ET
Consolidated Research: 2018 Summary Expectations for Murphy Oil, REGENXBIO, CRA International,Inc, Carriage Services, CONMED, and BioDelivery Sciences International — Fundamental Analysis, Key Perform
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Murphy Oil Corporation (NYSE:MUR), REGENXBIO Inc. (NASDAQ:RGNX), CRA...
Nov 07, 2018 03:05 pm ET
Alexandria Real Estate Equities, Inc. Announces Development of New Build-to-Suit at the Alexandria Life Science and Translational Research Center at 9800 Medical Center Drive with Signing of 15-Year,
PASADENA, Calif., Nov. 7, 2018 /PRNewswire/ -- Alexandria Real Estate Equities, Inc. (NYSE: ARE), an urban office REIT uniquely focused on collaborative life science and technology campuses in AAA innovation cluster locations, today announced that it has kicked off the development of a 175,000 RSF Class A property on its flagship Maryland campus, the Alexandria Life Science and Translational Research Center at 9800 Medical Center Drive, with the signing of a long-term lease with REGENXBIO Inc. (NASDAQ: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the
Nov 07, 2018 03:05 pm ET
REGENXBIO Reports Third Quarter 2018 Financial and Operating Results and Announces Initiation of Phase I/II Clinical Trial for RGX-121 for the Treatment of MPS II
ROCKVILLE, Md., Nov. 7, 2018 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced financial results for the quarter ended September 30, 2018 and recent operational highlights, including updates from its ongoing clinical trials.
Nov 06, 2018 06:00 am ET
REGENXBIO to Present at Upcoming Investor Conferences
ROCKVILLE, Md., Nov. 6, 2018 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will present at the following November investor conferences:
Nov 05, 2018 06:00 am ET
REGENXBIO and Abeona Therapeutics Announce Worldwide Exclusive Licenses for the Treatment of Four Rare Lysosomal Storage Disorders Using NAV AAV9 Vector
ROCKVILLE, Md., Nov. 5, 2018 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, and Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced a license agreement to REGENXBIO's NAV AAV9 vector for the treatment of four diseases: Sanfilippo syndrome type A (MPS IIIA), Sanfilippo syndrom
Oct 31, 2018 04:05 pm ET
REGENXBIO to Host Conference Call on November 7 to Discuss Third Quarter 2018 Financial Results and Recent Operational Highlights
ROCKVILLE, Md., Oct. 31, 2018 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will host a conference call on Wednesday, November 7, 2018 at 4:30 p.m. ET to discuss its financial results for the quarter ended September 30, 2018 and recent operational highlights.
Oct 26, 2018 06:10 pm ET
REGENXBIO Announces Additional Positive Interim Phase I Trial Update for RGX-314 for the Treatment of Wet AMD at the American Academy of Ophthalmology 2018 Annual Meeting
ROCKVILLE, Md., Oct. 26, 2018 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced updated results from the ongoing Phase I study of RGX-314 for the treatment of wet age-related macular degeneration (wet AMD).
Oct 22, 2018 07:00 am ET
REGENXBIO Announces Exclusive Worldwide License with Ultragenyx for the Treatment of CDKL5 Deficiency Disorder Using NAV Vectors
ROCKVILLE, Md., Oct. 22, 2018 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that Ultragenyx Pharmaceutical Inc. has exercised an option for an exclusive worldwide license to REGENXBIO's NAV Vectors, including NAV AAV9, for the treatment of CDKL5 Deficiency Disorder (CDD).
Oct 18, 2018 09:20 am ET
Detailed Research: Economic Perspectives on Control4, REGENXBIO, Ferro, Kadmon, Hemispherx BioPharma, and Murphy Oil — What Drives Growth in Today's Competitive Landscape
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Control4 Corporation (NASDAQ:CTRL), REGENXBIO Inc. (NASDAQ:RGNX), Ferro...
Oct 04, 2018 07:00 am ET
REGENXBIO Announces Completion of Dosing of Fourth Cohort in Phase I Clinical Trial of RGX-314 Gene Therapy for Wet AMD
ROCKVILLE, Md., Oct. 4, 2018 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced it has completed dosing of the fourth cohort of six patients in a Phase I clinical trial evaluating RGX-314 for the treatment of wet age-related macular degeneration (wet AMD or nAMD). A total of 24 subjects have been dosed in the trial. The Company also announced that an updated summary of Phase I study results, including addit
Oct 02, 2018 04:05 pm ET
REGENXBIO to Present at the Chardan 2nd Annual Genetic Medicines Conference
ROCKVILLE, Md., Oct. 2, 2018 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will present at the Chardan 2nd Annual Genetic Medicines Conference on Tuesday, October 9, 2018 at 4:15 p.m. ET at the Westin Grand Central, New York.
Sep 06, 2018 04:05 pm ET
REGENXBIO to Present at Upcoming Investor Conferences
ROCKVILLE, Md., Sept. 6, 2018 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will present at the following September investor conferences:
Aug 30, 2018 07:00 am ET
REGENXBIO Announces Pipeline Expansion with RGX-181 Gene Therapy for CLN2 Form of Batten Disease
ROCKVILLE, Md., Aug. 30, 2018 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced it is developing a new product candidate, RGX-181, for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease, one of the most common forms of Batten disease caused by mutations in the tripeptidyl peptidase 1 (TPP1) gene.
Aug 27, 2018 08:15 am ET
New Research: Key Drivers of Growth for REGENXBIO, Syndax Pharmaceuticals, Rowan Companies, CTS, Basic Energy Services, and Impinj — Factors of Influence, Major Initiatives and Sustained Production
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of REGENXBIO Inc. (NASDAQ:RGNX), Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX),...
Aug 14, 2018 04:01 pm ET
REGENXBIO Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
ROCKVILLE, Md., Aug. 14, 2018 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced the closing of its previously announced underwritten public offering of 2,700,000 shares of its common stock at a price to the public of $65.00 per share, as well as the exercise in full of the underwriters' option to purchase 405,000 additional shares at the public offering price. Including the option exercise, the total gross proce
Aug 10, 2018 07:30 am ET
REGENXBIO Announces Pricing Of Public Offering Of Common Stock
ROCKVILLE, Md., Aug. 10, 2018 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced the pricing of an underwritten public offering of 2,700,000 shares of its common stock at the price of $65.00 per share before underwriting discounts and commissions. The gross proceeds to REGENXBIO from the offering, before deducting the underwriting discounts and commissions and other offering expenses payable by REGENXBIO, are exp
Aug 08, 2018 04:05 pm ET
REGENXBIO Announces Proposed Public Offering Of Common Stock
ROCKVILLE, Md., Aug. 8, 2018 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it intends to offer and sell, subject to market conditions, $175,000,000 of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. In addition, REGEN
Aug 08, 2018 07:30 am ET
REGENXBIO Reports Second Quarter 2018 Financial and Operating Results and Interim Data from Ongoing Clinical Trials for Wet Age-Related Macular Degeneration and Homozygous Familial Hypercholesterolemi
ROCKVILLE, Md., Aug. 8, 2018 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced financial results for the quarter ended June 30, 2018 and recent operational highlights, including updates to interim data from its ongoing clinical trials.
Aug 07, 2018 05:43 pm ET
REGENXBIO to Host Conference Call and Webcast on August 8 to Discuss Second Quarter 2018 Financial and Operating Results and Interim Data from Ongoing Clinical Trials for Wet Age-Related Macular Degen
ROCKVILLE, Md., Aug. 7, 2018 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that its previously announced conference call and webcast on Wednesday, August 8, 2018 at 8:00 a.m. ET to discuss its financial results for the quarter ended June 30, 2018 and recent operational highlights will include interim data from ongoing clinical trials for wet age-related macular degeneration and homozygous familial hyperchole
Aug 01, 2018 07:00 am ET
REGENXBIO to Host Conference Call on August 8 to Discuss Second Quarter 2018 Financial Results and Recent Operational Highlights
ROCKVILLE, Md., Aug. 1, 2018 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will host a conference call on Wednesday, August 8, 2018 at 8:00 a.m. ET to discuss its financial results for the quarter ended June 30, 2018 and recent operational highlights.
Jun 25, 2018 08:25 am ET
Factors of Influence in 2018, Key Indicators and Opportunity within Immune Pharmaceuticals, Wells Fargo, Anadarko Petroleum, CTS, REGENXBIO, and TripAdvisor — New Research Emphasizes Economic Growth
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Immune Pharmaceuticals Inc. (NASDAQ:IMNP), Wells Fargo Company...
Jun 12, 2018 05:36 pm ET
REGENXBIO Receives FDA Fast Track Designation for RGX-111 Gene Therapy for the Treatment of Mucopolysaccharidosis Type I
ROCKVILLE, Md., June 12, 2018 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for RGX-111. RGX-111 is a novel, one-time investigational treatment for Mucopolysaccharidosis Type I (MPS I), that is designed to deliver the human iduronidase (IDUA) gene directly to the central nervous system (CNS) using the NAV AAV9 vector.
Jun 11, 2018 04:05 pm ET
REGENXBIO Receives $100 Million Accelerated License Payment Due to Acquisition of AveXis by Novartis
ROCKVILLE, Md., June 11, 2018 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it has received an accelerated license payment of $100 million under its license agreement (the License Agreement) with AveXis, Inc. (AveXis) for the development and commercialization of products to treat spinal muscular atrophy (SMA), due to the acquisition of AveXis by Novartis AG (Novartis).
Jun 04, 2018 06:03 pm ET
Netflix Set to Join S&P 100; Twitter to Join S&P 500; REGENXBIO to Join S&P SmallCap 600
NEW YORK, June 4, 2018 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 100, S&P 500 and S&P SmallCap 600 effective prior to the open of trading on Thursday, June 7:
May 29, 2018 04:05 pm ET
Alexandra Glucksmann Joins REGENXBIO Board of Directors
ROCKVILLE, Md., May 29, 2018 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced the appointment of Alexandra Glucksmann, Ph.D., to its board of directors, effective as of May 25, 2018.
May 15, 2018 07:30 am ET
REGENXBIO Joins the Mucopolysaccharidosis Community to Advance Research and Innovation
ROCKVILLE, Md., May 15, 2018 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today recognizes International Mucopolysaccharidosis (MPS) Awareness Day 2018, which is dedicated to raising awareness of MPS, a group of inherited lysosomal storage disorders that have been estimated to affect one in 25,000 births in the United States.
May 09, 2018 04:05 pm ET
REGENXBIO to Present at the Bank of America Merrill Lynch 2018 Healthcare Conference
ROCKVILLE, Md., May 9, 2018 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will present at the Bank of America Merrill Lynch 2018 Healthcare Conference on Tuesday, May 15, 2018 at 3:40 p.m. PT at the Encore Wynn in Las Vegas, NV. In addition, REGENXBIO senior management will be holding one-on-one meetings at the conference.
May 08, 2018 04:05 pm ET
REGENXBIO Reports First Quarter 2018 Financial Results and Recent Operational Highlights
ROCKVILLE, Md., May 8, 2018 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced financial results for the quarter ended March 31, 2018 and recent operational highlights.
May 02, 2018 07:00 am ET
REGENXBIO Receives FDA Fast Track Designation for RGX-121 Gene Therapy for the Treatment of Mucopolysaccharidosis Type II
ROCKVILLE, Md., May 2, 2018 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for RGX-121. RGX-121 is a novel, one-time investigational treatment for Mucopolysaccharidosis Type II (MPS II), also known as Hunter syndrome, that is designed to deliver the human iduronate 2-sulfatase (I2S) gene directly to the central nervous system
May 01, 2018 04:05 pm ET
REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2018 Financial Results and Recent Operational Highlights
ROCKVILLE, Md., May 1, 2018 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will host a conference call on Tuesday, May 8, 2018 at 4:30 p.m. ET to discuss its financial results for the quarter ended March 31, 2018 and recent operational highlights.
Mar 22, 2018 08:00 am ET
Consolidated Research: 2018 Summary Expectations for REGENXBIO, WD-40, Chesapeake Utilities, Astronics, Park-Ohio, and Cass Information — Fundamental Analysis, Key Performance Indications
NEW YORK, March 22, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of REGENXBIO Inc. (NASDAQ:RGNX), WD-40 Company (NASDAQ:WDFC),...
Mar 07, 2018 04:05 pm ET
REGENXBIO to Participate in Upcoming Investor Conferences
ROCKVILLE, Md., March 07, 2018 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.

Learn More